Post-Registration projects
Discovery and Preclinical Projects
Business development
clinical Projects
DNDi's Activities Worldwide
fundraising AND ADVOCACY
DNDi's Malaria Project:
A Model for Innovative Partnerships?
No single State, organisation, company, or community can meet malaria's challenges alone. Cooperation and coordination are important elements to ensure an effective and rapid response to control malaria. In line with DNDi's goals to meet the needs of people most threatened by neglected diseases, two antimalarial drugs have been delivered within the multi-partner Fixed-Dose, Artesunate-Based Combination Therapies (FACT) Project, which was created in 2002 under the umbrella of MSF and then transferred to DNDi in 2003 in coordination with the UNICEF-UNDP-World Bank-WHO Special Programme for Research and Training in Tropical Diseases (TDR).

As Executive Director of DNDi, Dr. Bernard Pécoul offers his take on how partnership is so valuable in addressing urgent needs for those affected by malaria.
Why Lead Platforms are Crucial to Boost Innovation for Neglected Diseases
Drug discovery is very much a 'numbers game'. To give a couple of examples:

1 • The chemical space inhabited by most drugs could be described as relatively small molecules (less than 500 Daltons) which contain some of the following elements: carbon, oxygen, phosphorus, sulfur, nitrogen, chlorine, fluorine, bromine...
Operational Challenges: Clinical Trial Partnerships in Africa
Developing new treatments for people suffering from sleeping sickness (HAT) or visceral leishmaniasis (VL) is a long and difficult process, especially when clinical trials are carried out in rural areas in Africa where health infrastructure is limited or non-existent...
Paving the Way to Win-Win Partnerships
The DNDi mission is to develop new therapies for the most neglected diseases as a response to the blatant medical needs of patients belonging to populations amongst the poorest in the world. Because these patients lie completely outside of the global pharmaceutical market, the traditional profit-based approach cannot be implemented, resulting in the absence of any significant efforts to develop drugs for diseases such as sleeping sickness or leishmaniasis.

Published by Drugs for Neglected Diseases Initiative - 15 Chemin Louis-Dunant 1202 Geneva Switzerland - Photo credits: DNDi unless otherwise stated - Editor: Sadia Kaenzig - Tel: +41 22 906 9230 - Fax: +41 22 906 9231 -